Alzheimer’s Breakthrough or FDA Mistake?
When the FDA convened an independent commission in 2020 to decide whether a new Alzheimer’s drug called Aduhelm (generic name aducanumab) should be approved, ten out of the 11 experts on the commission said "No." As for that eleventh expert? This commission member said the verdict on the drug's efficacy in improving the brain health [...]